Nasal polyps in dogs are small pink growths that come from a dog’s moist nose tissue lining. Thankfully, the growths are benign. Unfortunately, the precise cause of the condition is not known. Usually ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of ...

x ray of sinusitis and nasal polyps Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and ...

Please provide your email address to receive an email when new articles are posted on . Extended use of omalizumab up to 1 year showed efficacy for the treatment of uncontrolled chronic rhinosinusitis ...

Please provide your email address to receive an email when new articles are posted on . Mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis with nasal polyps ...

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...

A significant link was found regarding incidence of diabetes and chronic rhinosinusitis (CRS) with nasal polyps, whereas CRS without nasal polyps was not associated with diabetes. Patients with ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

YARDLEY, Pa., April 27, 2021 /PRNewswire/ — Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...